Growth has to read as a system — fertility networks

Consult growth is documented and cycle economics are not

PRESENTATION — WHAT THE OPERATOR SEES

A process is in view and the pack is built on consults. A buyer prices cycles, capacity and the durability of the network's local brands — and in a portfolio assembled from legacy clinics, the first question is whether anything can be read across them at all.

DIFFERENTIAL — LIKELY CAUSES, MOST LIKELY FIRST

01
The trailing history cannot be re-run by a stranger

Definitions that differ by clinic and a platform view rebuilt by hand each month do not survive diligence. The trend line is only as good as the consistency underneath it.

One definition set applied identically across every brand, with the arithmetic shown and the pack reconciling to the income statement, is what a buyer's analyst actually reads.

No published distribution — ADMEN source register, /sources/

NOT THIS IF — One definition set already runs across the network and the pack reconciles.
02
Growth is reported in consults, and the income statement runs on cycles

A growth story told in consults invites the buyer to build the cycle bridge himself, and he will build it conservatively. Cost per cycle start and revenue per cycle are the figures that carry the multiple.

Consult-to-cycle-start conversion, cost per cycle start and revenue per cycle are all constructible from the network's own systems once the definitions are common.

No published distribution — ADMEN source register, /sources/

NOT THIS IF — The pack already reports cycle starts, cost per cycle start and revenue per cycle by clinic.
03
Growth came from acquisition rather than from same-clinic improvement

Volume that grew because two clinics were bought is a different asset from volume that grew because the same clinics improved. Both are real; only the second is evidence of a re-runnable system.

Decompose growth into acquired clinics, capacity additions and same-clinic change. The third component is the one that prices as a system.

No published distribution — ADMEN source register, /sources/

NOT THIS IF — Same-clinic, same-capacity cycle starts grew materially over the period.
04
Outcome presentation across the brands is a diligence exposure

Inconsistent published outcome claims across legacy sites are a compliance question, a marketing question and a clinical question at once, and in diligence they are read as governance risk rather than as marketing untidiness.

The outcome figures that circulate in this market are frequently clinic-selected and not comparable across programmes. A network that states its denominators and says plainly what a figure cannot be used to compare is describing a governance position, not a limitation.

No published distribution — ADMEN source register, /sources/

NOT THIS IF — Outcome publication already runs through one standing clinical and compliance review across every brand.

HOW TO TELL THEM APART

How to tell these apart in your own numbers

Each of these is a measurement you can run yourself, without us.

01 · The trailing history cannot be re-run by a stranger

Have somebody outside the finance team rebuild one month of the platform pack from source systems using only the written definitions.

CONFIRMS IF

They cannot reproduce it, or they produce a different number at any clinic.

EXCLUDES IF

It reconciles across every brand.

02 · Growth is reported in consults, and the income statement runs on cycles

Build cycle starts, cost per cycle start and revenue per cycle by clinic for thirty-six months on one definition set.

CONFIRMS IF

They cannot be built, or they have never been reported.

EXCLUDES IF

They are already in the monthly pack.

03 · Growth came from acquisition rather than from same-clinic improvement

Decompose growth into acquired clinics, capacity additions and same-clinic change, thirty-six months.

CONFIRMS IF

Almost all of it sits in the first two components.

EXCLUDES IF

Same-clinic change carried a meaningful share.

04 · Outcome presentation across the brands is a diligence exposure

Audit every outcome claim published under every brand, with its denominator and its approval trail.

CONFIRMS IF

Claims differ in basis across brands, or no approval trail exists.

EXCLUDES IF

One review process governs all of it and the trail is documented.

WHAT RESOLVES EACH

What resolves this, and how you will know it resolved

The trailing history cannot be re-run by a stranger	Rx 04 · marketing attribution →	One definition set across every brand, one automated pack, arithmetic shown, reconciled to the income statement.
Growth is reported in consults, and the income statement runs on cycles	Rx 04 · marketing attribution →	Cycle starts, cost per cycle start and revenue per cycle reported by clinic — the figures the income statement actually responds to.
Growth came from acquisition rather than from same-clinic improvement	Rx 05 · preparing for sale →	Growth decomposed in the narrative rather than asserted, so the component a buyer can re-run is visible and the component he cannot is not oversold.
Outcome presentation across the brands is a diligence exposure	Rx 05 · preparing for sale →	Outcome publication governed as a standing clinical and compliance step across every brand, with the denominators stated and the approval trail documented.

WHAT "RESOLVED" LOOKS LIKE — Cycle starts, cost per cycle start and revenue per cycle, by clinic, on one definition set

MEDIAN

Not published in a comparable form.

TOP DECILE

Not published, and a modelled multiple is a model rather than a comparable.

TARGET

Thirty-six months on one definition set across every brand, a pack that reconciles, growth decomposed, and one governed outcome-publication process — the instrumentation IVF network operators should be running anyway, not something built for the process.

No published distribution — ADMEN source register, /sources/

HOW THIS DIFFERS BY SCALE

How this differs by scale

Single site	One clinic sells on its physicians and its outcomes. Portability of both is the whole conversation.
Group	Definition drift between a handful of clinics is the finding that most often delays a process.
Platform	The buyer is buying the reporting layer as much as the clinics. A platform view that cannot be re-run is priced as risk.

OTHER PRESENTATIONS — FERTILITY NETWORKS

A differential narrows the field. It does not replace the examination — that is what the six weeks are for. Every figure above is an industry reference range, not a client's numbers; those stay sealed. Sources are set out at /sources.

APPLY — 6 / QUARTER →